Department of Dermatology, University of Massachusetts, Worcester, Massachusetts; and.
Departments of Surgery, and.
Dermatol Surg. 2021 Jan 1;47(1):1-5. doi: 10.1097/DSS.0000000000002417.
Recent studies demonstrate comparable outcomes of Mohs micrographic surgery (MMS) versus local excision (LE) for melanoma in situ. These studies are limited by their focus on the head and neck.
The primary objective was to compare 5-year overall and melanoma-specific mortality among patients with melanoma in situ of the trunk or extremities who undergo MMS versus LE. The secondary objective was to compare 5-year local recurrence among the same cohort of patients who undergo MMS versus LE.
The Surveillance, Epidemiology, and End Results (SEER) database (2000-2015) was queried to identify patients who underwent MMS versus LE for melanoma in situ of the trunk, upper extremities, or lower extremities. Outcomes were 5-year recurrence, melanoma-specific mortality, and overall mortality. Multivariable regression analyses were performed.
Thirty three thousand nine hundred eighty-three patients underwent surgical treatment (MMS 3%; LE 97%). In adjusted analyses, there was no difference in local recurrence (hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.56-1.78), melanoma-specific mortality (HR 0.89, 95% CI 0.12-6.47), nor overall mortality (HR 1.10, 95% CI 0.82-1.48) between MMS versus LE.
There is no difference of 5-year local recurrence, melanoma-specific mortality, nor overall mortality associated with MMS versus LE for melanoma in situ of the trunk or extremities.
最近的研究表明,Mohs 显微外科手术(MMS)与局部切除术(LE)治疗原位黑色素瘤的结果相当。这些研究的局限性在于它们只关注头颈部。
主要目的是比较接受 MMS 与 LE 治疗的躯干或四肢原位黑色素瘤患者的 5 年总生存率和黑色素瘤特异性死亡率。次要目的是比较接受 MMS 与 LE 治疗的同一队列患者的 5 年局部复发率。
查询监测、流行病学和最终结果(SEER)数据库(2000-2015 年),以确定接受 MMS 与 LE 治疗的躯干、上肢或下肢原位黑色素瘤患者。结局为 5 年复发率、黑色素瘤特异性死亡率和总死亡率。进行多变量回归分析。
33983 例患者接受了手术治疗(MMS 3%,LE 97%)。在调整后的分析中,局部复发(风险比 [HR] 1.00,95%置信区间 [CI] 0.56-1.78)、黑色素瘤特异性死亡率(HR 0.89,95% CI 0.12-6.47)和总死亡率(HR 1.10,95% CI 0.82-1.48)在 MMS 与 LE 之间无差异。
MMS 与 LE 治疗躯干或四肢原位黑色素瘤在 5 年局部复发、黑色素瘤特异性死亡率和总死亡率方面无差异。